<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">34076832</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-7373</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>153</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neuro-oncology</Title>
          <ISOAbbreviation>J Neurooncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic Cerebellar Degeneration (PCD) associated with PCA-1 antibodies in established cancer patients.</ArticleTitle>
        <Pagination>
          <StartPage>441</StartPage>
          <EndPage>446</EndPage>
          <MedlinePgn>441-446</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11060-021-03779-7</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Paraneoplastic cerebellar degeneration (PCD) is a rare set of neurological disorders arising from tumor-associated autoimmunity against antigens within the cerebellum. Anti-Purkinje cell cytoplasmic antibody 1 (PCA-1), or anti-Yo, is the most commonly linked antibody and is classically associated with breast and ovarian cancers.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Medical records of patients at our institution who developed PCA-1 associated PCD were reviewed. Clinical information, including cancer history, cancer-directed treatment, and serum and CSF titers of PCA-1 antibody were extracted.</AbstractText>
          <AbstractText Label="CASES" NlmCategory="METHODS">We report a series of cases of PCA-1 associated PCD in patients with known breast or ovarian cancer diagnosis not receiving immunotherapy. These cases highlight aspects of PCA-1 paraneoplastic syndrome such as triggering by cytotoxic chemotherapy or surgery, the possibility of tumor recurrence and the association with development of a second cancer.</AbstractText>
          <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Diagnosis of the syndrome requires neurological workup with lumbar puncture (LP) with cerebrospinal fluids (CSF) studies, serum and CSF paraneoplastic antibody panel, and neuroimaging. Inpatient admission for prompt workup and initiation of treatment is recommended. Treatment most commonly includes immunosuppression with corticosteroids, plasmapheresis, and/or intravenous immune globulin (IVIG); however, we postulate that other immune modulating treatments may warrant consideration.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These cases highlight the need for early recognition of the syndrome in patients receiving nonimmune based chemotherapy, for prompt workup and treatment.</AbstractText>
          <CopyrightInformation>Â© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lehner</LastName>
            <ForeName>Michael J</ForeName>
            <Initials>MJ</Initials>
            <Identifier Source="ORCID">0000-0001-5575-7105</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gheeya</LastName>
            <ForeName>Jinesh S</ForeName>
            <Initials>JS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siddiqui</LastName>
            <ForeName>Bilal A</ForeName>
            <Initials>BA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tummala</LastName>
            <ForeName>Sudhakar</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 0431, Houston, TX, 77030, USA. stummala@mdanderson.org.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Neurooncol</MedlineTA>
        <NlmUniqueID>8309335</NlmUniqueID>
        <ISSNLinking>0167-594X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000912">Antibodies, Neoplasm</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C505096">PCA-1 antigen, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000719013">anti-Yo autoantibodies</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000912" MajorTopicYN="N">Antibodies, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000951" MajorTopicYN="N">Antigens, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010051" MajorTopicYN="Y">Ovarian Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020362" MajorTopicYN="Y">Paraneoplastic Cerebellar Degeneration</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cancer</Keyword>
        <Keyword MajorTopicYN="N">Cerebellar degeneration</Keyword>
        <Keyword MajorTopicYN="N">PCA-1 antibodies</Keyword>
        <Keyword MajorTopicYN="N">Paraneoplastic</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>2</Day>
          <Hour>12</Hour>
          <Minute>26</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34076832</ArticleId>
        <ArticleId IdType="doi">10.1007/s11060-021-03779-7</ArticleId>
        <ArticleId IdType="pii">10.1007/s11060-021-03779-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Jarius S, Wildemann B (2015) âMedusa head ataxiaâ: The expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook. J Neuroinflammation. 12(1):1â22. https://doi.org/10.1186/s12974-015-0358-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-015-0358-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA (1978) Selective expression of purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. NEJM 299:230â234. https://doi.org/10.1056/NEJM198603273141302</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM198603273141302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Posner JB (1991) Paraneoplastic syndromes. Neurol Clin 9(4):919â936. https://doi.org/10.1016/s0733-8619(18)30257-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0733-8619(18)30257-3</ArticleId>
            <ArticleId IdType="pubmed">1758432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J, Rosenfeld MR (2008) Paraneoplastic syndromes of the CNS. Lancet Neurol 7(4):327â340. https://doi.org/10.1016/S1474-4422(08)70060-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(08)70060-7</ArticleId>
            <ArticleId IdType="pubmed">18339348</ArticleId>
            <ArticleId IdType="pmc">2367117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monstad SE, Storstein A, DÃ¸rum A et al (2006) Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin Exp Immunol 144(1):53â58. https://doi.org/10.1111/j.1365-2249.2006.03031.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2249.2006.03031.x</ArticleId>
            <ArticleId IdType="pubmed">16542365</ArticleId>
            <ArticleId IdType="pmc">1809634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psimaras D, Carpentier AF, Rossi C (2010) Cerebrospinal fluid study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry 81(1):42â45. https://doi.org/10.1136/jnnp.2008.159483</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2008.159483</ArticleId>
            <ArticleId IdType="pubmed">19324868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aboul-Enein F, HÃ¶ftberger R, Buxhofer-Ausch V et al (2008) Neocortical neurones may be targeted by immune attack in anti-Yo paraneoplastic syndrome. Neuropathol Appl Neurobiol 34(2):248â252. https://doi.org/10.1111/j.1365-2990.2007.00909.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2990.2007.00909.x</ArticleId>
            <ArticleId IdType="pubmed">17995920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giometto B, Marchiori GC, Nicolao P et al (1997) Sub-acute cerebellar degeneration with anti-Yo autoantibodies: Immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathol Appl Neurobiol 23(6):468â474. https://doi.org/10.1111/j.1365-2990.1997.tb01323.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2990.1997.tb01323.x</ArticleId>
            <ArticleId IdType="pubmed">9460712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vernino S (1991) Paraneoplastic cerebellar degeneration. Handb Clin Neurol 2012(103):215â223. https://doi.org/10.1016/B978-0-444-51892-7.00013-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/B978-0-444-51892-7.00013-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Delattre JY, Antoine JC et al (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75(8):1135â1140. https://doi.org/10.1136/jnnp.2003.034447</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2003.034447</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
            <ArticleId IdType="pmc">1739186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venkatraman A, Opal P (2016) Paraneoplastic cerebellar degeneration with anti-Yo antibodies â a review. Ann Clin Transl Neurol 3(8):655â663. https://doi.org/10.1002/acn3.328</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acn3.328</ArticleId>
            <ArticleId IdType="pubmed">27606347</ArticleId>
            <ArticleId IdType="pmc">4999597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojas I, Graus F, Keime-Guibert F et al (2000) Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 55(5):713â715. https://doi.org/10.1212/WNL.55.5.713</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.55.5.713</ArticleId>
            <ArticleId IdType="pubmed">10980743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Beukelaar JW, Smitt PAS (2006) Managing Paraneoplastic Neurological Disorders. Oncologist 11(3):292â305. https://doi.org/10.1634/theoncologist.11-3-292</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.11-3-292</ArticleId>
            <ArticleId IdType="pubmed">16549814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerard Power D, Paul McVey G, William Delaney D et al (2008) Papillary serous carcinomas of the uterine cervix and paraneoplastic cerebellar degeneration: A report of two cases. Acta Oncol (Madr) 47(8):1590â1593. https://doi.org/10.1080/02841860701774974</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/02841860701774974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abele M, BÃ¼rk K, SchÃ¶ls L et al (2002) The aetiology of sporadic adult-onset ataxia. Brain 125(5):961â968. https://doi.org/10.1093/brain/awf107</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awf107</ArticleId>
            <ArticleId IdType="pubmed">11960886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doherty CM, Forbes RB (2014) Diagnostic lumbar puncture. Ulster Med J 83(2):93â102</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25075138</ArticleId>
            <ArticleId IdType="pmc">4113153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shamsâili S, De Beukelaar J, Gratama JW et al (2006) An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol. 253(1):16â20. https://doi.org/10.1007/s00415-005-0882-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-005-0882-0</ArticleId>
            <ArticleId IdType="pubmed">16444604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson EH, Weninger W, Hunter CA (2010) Trafficking of immune cells in the central nervous system. J Clin Invest 120(5):1368â1379. https://doi.org/10.1172/JCI41911</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI41911</ArticleId>
            <ArticleId IdType="pubmed">20440079</ArticleId>
            <ArticleId IdType="pmc">20440079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stern JNH, Yaari G, Vander Heiden JA et al (2014) B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci Transl Med 6(248):1â11. https://doi.org/10.1126/scitranslmed.3008879</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3008879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brandstadter R, Sand IK (2017) The use of natalizumab for multiple sclerosis. Neuropsychiatr Dis Treat 13:1691â1702. https://doi.org/10.2147/NDT.S114636</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/NDT.S114636</ArticleId>
            <ArticleId IdType="pubmed">28721050</ArticleId>
            <ArticleId IdType="pmc">5499927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aktas O, KÃ¼ry P, Kieseier B, Hartung HP (2010) Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 6(7):373â382. https://doi.org/10.1038/nrneurol.2010.76</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneurol.2010.76</ArticleId>
            <ArticleId IdType="pubmed">20551946</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">34076832</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-7373</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>153</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neuro-oncology</Title>
          <ISOAbbreviation>J Neurooncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic Cerebellar Degeneration (PCD) associated with PCA-1 antibodies in established cancer patients.</ArticleTitle>
        <Pagination>
          <StartPage>441</StartPage>
          <EndPage>446</EndPage>
          <MedlinePgn>441-446</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11060-021-03779-7</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Paraneoplastic cerebellar degeneration (PCD) is a rare set of neurological disorders arising from tumor-associated autoimmunity against antigens within the cerebellum. Anti-Purkinje cell cytoplasmic antibody 1 (PCA-1), or anti-Yo, is the most commonly linked antibody and is classically associated with breast and ovarian cancers.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Medical records of patients at our institution who developed PCA-1 associated PCD were reviewed. Clinical information, including cancer history, cancer-directed treatment, and serum and CSF titers of PCA-1 antibody were extracted.</AbstractText>
          <AbstractText Label="CASES" NlmCategory="METHODS">We report a series of cases of PCA-1 associated PCD in patients with known breast or ovarian cancer diagnosis not receiving immunotherapy. These cases highlight aspects of PCA-1 paraneoplastic syndrome such as triggering by cytotoxic chemotherapy or surgery, the possibility of tumor recurrence and the association with development of a second cancer.</AbstractText>
          <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Diagnosis of the syndrome requires neurological workup with lumbar puncture (LP) with cerebrospinal fluids (CSF) studies, serum and CSF paraneoplastic antibody panel, and neuroimaging. Inpatient admission for prompt workup and initiation of treatment is recommended. Treatment most commonly includes immunosuppression with corticosteroids, plasmapheresis, and/or intravenous immune globulin (IVIG); however, we postulate that other immune modulating treatments may warrant consideration.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These cases highlight the need for early recognition of the syndrome in patients receiving nonimmune based chemotherapy, for prompt workup and treatment.</AbstractText>
          <CopyrightInformation>Â© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lehner</LastName>
            <ForeName>Michael J</ForeName>
            <Initials>MJ</Initials>
            <Identifier Source="ORCID">0000-0001-5575-7105</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gheeya</LastName>
            <ForeName>Jinesh S</ForeName>
            <Initials>JS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siddiqui</LastName>
            <ForeName>Bilal A</ForeName>
            <Initials>BA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tummala</LastName>
            <ForeName>Sudhakar</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 0431, Houston, TX, 77030, USA. stummala@mdanderson.org.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Neurooncol</MedlineTA>
        <NlmUniqueID>8309335</NlmUniqueID>
        <ISSNLinking>0167-594X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000912">Antibodies, Neoplasm</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C505096">PCA-1 antigen, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000719013">anti-Yo autoantibodies</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000912" MajorTopicYN="N">Antibodies, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000951" MajorTopicYN="N">Antigens, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010051" MajorTopicYN="Y">Ovarian Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020362" MajorTopicYN="Y">Paraneoplastic Cerebellar Degeneration</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cancer</Keyword>
        <Keyword MajorTopicYN="N">Cerebellar degeneration</Keyword>
        <Keyword MajorTopicYN="N">PCA-1 antibodies</Keyword>
        <Keyword MajorTopicYN="N">Paraneoplastic</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>2</Day>
          <Hour>12</Hour>
          <Minute>26</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34076832</ArticleId>
        <ArticleId IdType="doi">10.1007/s11060-021-03779-7</ArticleId>
        <ArticleId IdType="pii">10.1007/s11060-021-03779-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Jarius S, Wildemann B (2015) âMedusa head ataxiaâ: The expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook. J Neuroinflammation. 12(1):1â22. https://doi.org/10.1186/s12974-015-0358-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-015-0358-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA (1978) Selective expression of purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. NEJM 299:230â234. https://doi.org/10.1056/NEJM198603273141302</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM198603273141302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Posner JB (1991) Paraneoplastic syndromes. Neurol Clin 9(4):919â936. https://doi.org/10.1016/s0733-8619(18)30257-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0733-8619(18)30257-3</ArticleId>
            <ArticleId IdType="pubmed">1758432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J, Rosenfeld MR (2008) Paraneoplastic syndromes of the CNS. Lancet Neurol 7(4):327â340. https://doi.org/10.1016/S1474-4422(08)70060-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(08)70060-7</ArticleId>
            <ArticleId IdType="pubmed">18339348</ArticleId>
            <ArticleId IdType="pmc">2367117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monstad SE, Storstein A, DÃ¸rum A et al (2006) Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin Exp Immunol 144(1):53â58. https://doi.org/10.1111/j.1365-2249.2006.03031.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2249.2006.03031.x</ArticleId>
            <ArticleId IdType="pubmed">16542365</ArticleId>
            <ArticleId IdType="pmc">1809634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psimaras D, Carpentier AF, Rossi C (2010) Cerebrospinal fluid study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry 81(1):42â45. https://doi.org/10.1136/jnnp.2008.159483</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2008.159483</ArticleId>
            <ArticleId IdType="pubmed">19324868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aboul-Enein F, HÃ¶ftberger R, Buxhofer-Ausch V et al (2008) Neocortical neurones may be targeted by immune attack in anti-Yo paraneoplastic syndrome. Neuropathol Appl Neurobiol 34(2):248â252. https://doi.org/10.1111/j.1365-2990.2007.00909.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2990.2007.00909.x</ArticleId>
            <ArticleId IdType="pubmed">17995920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giometto B, Marchiori GC, Nicolao P et al (1997) Sub-acute cerebellar degeneration with anti-Yo autoantibodies: Immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathol Appl Neurobiol 23(6):468â474. https://doi.org/10.1111/j.1365-2990.1997.tb01323.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2990.1997.tb01323.x</ArticleId>
            <ArticleId IdType="pubmed">9460712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vernino S (1991) Paraneoplastic cerebellar degeneration. Handb Clin Neurol 2012(103):215â223. https://doi.org/10.1016/B978-0-444-51892-7.00013-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/B978-0-444-51892-7.00013-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Delattre JY, Antoine JC et al (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75(8):1135â1140. https://doi.org/10.1136/jnnp.2003.034447</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2003.034447</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
            <ArticleId IdType="pmc">1739186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venkatraman A, Opal P (2016) Paraneoplastic cerebellar degeneration with anti-Yo antibodies â a review. Ann Clin Transl Neurol 3(8):655â663. https://doi.org/10.1002/acn3.328</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acn3.328</ArticleId>
            <ArticleId IdType="pubmed">27606347</ArticleId>
            <ArticleId IdType="pmc">4999597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojas I, Graus F, Keime-Guibert F et al (2000) Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 55(5):713â715. https://doi.org/10.1212/WNL.55.5.713</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.55.5.713</ArticleId>
            <ArticleId IdType="pubmed">10980743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Beukelaar JW, Smitt PAS (2006) Managing Paraneoplastic Neurological Disorders. Oncologist 11(3):292â305. https://doi.org/10.1634/theoncologist.11-3-292</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.11-3-292</ArticleId>
            <ArticleId IdType="pubmed">16549814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerard Power D, Paul McVey G, William Delaney D et al (2008) Papillary serous carcinomas of the uterine cervix and paraneoplastic cerebellar degeneration: A report of two cases. Acta Oncol (Madr) 47(8):1590â1593. https://doi.org/10.1080/02841860701774974</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/02841860701774974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abele M, BÃ¼rk K, SchÃ¶ls L et al (2002) The aetiology of sporadic adult-onset ataxia. Brain 125(5):961â968. https://doi.org/10.1093/brain/awf107</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awf107</ArticleId>
            <ArticleId IdType="pubmed">11960886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doherty CM, Forbes RB (2014) Diagnostic lumbar puncture. Ulster Med J 83(2):93â102</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25075138</ArticleId>
            <ArticleId IdType="pmc">4113153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shamsâili S, De Beukelaar J, Gratama JW et al (2006) An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol. 253(1):16â20. https://doi.org/10.1007/s00415-005-0882-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-005-0882-0</ArticleId>
            <ArticleId IdType="pubmed">16444604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson EH, Weninger W, Hunter CA (2010) Trafficking of immune cells in the central nervous system. J Clin Invest 120(5):1368â1379. https://doi.org/10.1172/JCI41911</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI41911</ArticleId>
            <ArticleId IdType="pubmed">20440079</ArticleId>
            <ArticleId IdType="pmc">20440079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stern JNH, Yaari G, Vander Heiden JA et al (2014) B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci Transl Med 6(248):1â11. https://doi.org/10.1126/scitranslmed.3008879</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3008879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brandstadter R, Sand IK (2017) The use of natalizumab for multiple sclerosis. Neuropsychiatr Dis Treat 13:1691â1702. https://doi.org/10.2147/NDT.S114636</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/NDT.S114636</ArticleId>
            <ArticleId IdType="pubmed">28721050</ArticleId>
            <ArticleId IdType="pmc">5499927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aktas O, KÃ¼ry P, Kieseier B, Hartung HP (2010) Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 6(7):373â382. https://doi.org/10.1038/nrneurol.2010.76</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneurol.2010.76</ArticleId>
            <ArticleId IdType="pubmed">20551946</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
